---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-010525"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T03:11:12.766745+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics licenses IL-17A/F antibodies from Paragon; up to $22M in milestones

## Summary
- Exclusive worldwide license to develop and commercialize Paragon's anti-IL-17A/F antibodies.
- Milestone payments up to $22M, including $1.5M for candidate nomination and $2.5M for first Phase 1 dosing.
- Low single-digit royalty on antibody products; royalty term up to 12 years after first sale.
- Paragon agrees not to conduct new anti-IL-17A/F campaigns in the field for at least 5 years.
- Company may terminate agreement on 60 days' notice; termination for breach or insolvency.

## SEC filing metadata
- accession: 0001213900-25-010525
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390025010525/0001213900-25-010525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390025010525/ea0229970-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-010525
- JSON: https://secwatch.observer/filing/0001213900-25-010525.json
- Plain text: https://secwatch.observer/filing/0001213900-25-010525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.